Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$24 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-226.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
59.1
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$0.2
EPS
$-0.7
Face value
--
Shares outstanding
32,736,300
CFO
$-73.26 Mln
EBITDA
$-80.04 Mln
Net Profit
$-81.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyclo Therapeutics (CYTH)
| 22.1 | -6.3 | 26.4 | -48.5 | -36.8 | -49.1 | -35.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Cyclo Therapeutics (CYTH)
| -62.6 | 12.0 | -61.9 | -14.3 | -87.2 | -57.1 | 128.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta... cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Read more
CEO & Director
Mr. N. Scott Fine
CEO & Director
Mr. N. Scott Fine
Headquarters
Gainesville, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cyclo Therapeutics Inc (CYTH) is $0.72 (NASDAQ) as of 27-Mar-2025 09:30 EDT. Cyclo Therapeutics Inc (CYTH) has given a return of -36.77% in the last 3 years.
Since, TTM earnings of Cyclo Therapeutics Inc (CYTH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.85
|
3.56
|
|
2023
|
-1.97
|
8.31
|
|
2022
|
-0.79
|
16.36
|
|
2021
|
-1.68
|
1.53
|
|
2020
|
-2.60
|
2.22
|
The 52-week high and low of Cyclo Therapeutics Inc (CYTH) are Rs -- and Rs -- as of 03-Apr-2026.
Cyclo Therapeutics Inc (CYTH) has a market capitalisation of $ 24 Mln as on 27-Mar-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Cyclo Therapeutics Inc (CYTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.